10results about How to "Improve pathological condition" patented technology

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a medicine patch needle for preventing and treating allergic rhinitis and a preparation method and application thereof. The medicine patch needle mainly comprises a traditional Chinese medicine composition and a medicine patch thumbtack needle, and the traditional Chinese medicine composition is prepared from, by weight, 30-60 parts of radix astragali, 15-30 parts of radix angelicae sinensis, 10-25 parts of radix saposhnikoviae, 10-30 parts of rhizoma atractylodis, 10-30 parts of rhizoma acori graminei, 5-15 parts of herba asari, 10-30 parts of rhizoma chuanxiong, 10-20 parts of radix angelicae and 1-5 parts of borneol. The medicine needle patch can be used for preventing and treating allergic rhinitis, mild and lasting acupuncture stimulation is achieved on the skin part of the acupoint, the medicine can rapidly enter the acupoint along with the needle hole, in other words, the acupoint achieves the effects of harmonizing qi and blood, relieving stuffy nose and removing pathogenic qi under the dual action of the acupuncture stimulation and the medicine, and the medicine needle patch has the remarkable preventing and treating effect on the allergic rhinitis.

The application discloses application of an antisense oligonucleotide in preparation of a drug for treating Alzheimer's disease, and belongs to the technical field of biological medicines. The antisense oligonucleotide comprises at least one of ASO1, ASO2 and ASO3, and the sequences of the ASO1, ASO2 and ASO3 are respectively shown as SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3. The antisense oligonucleotide can reduce the expression level of amyloid precursor protein and reduce the generation of beta-amyloid plaque in brain tissue. The application can improve the pathological state related to Alzheimer's disease by targeted regulation of the expression of amyloid precursor protein, and can be used alone or in combination with other active ingredients for treating Alzheimer's disease, has good therapeutic effect and application prospect, and provides a new way and selection for the treatment of Alzheimer's disease.

The invention discloses application of cannabidiol in preparation of a medicine for treating polycystic ovarian syndrome. Experiments on mice with dihydrotestosterone-induced polycystic ovarian syndrome show that cannabidiol can relieve the disorder state of the estrus cycle, improve the change of ovarian polycystic samples, reduce the number of atresia follicles, increase the number of corpus luteum, improve the level of serum progestational hormone, improve glucose and lipid metabolism and relieve anxiety for the first time; the traditional Chinese medicine composition can be used for treating polycystic ovarian syndrome. The invention provides a brand new thought for research and development of medicines for treating the polycystic ovarian syndrome, and has a wide application prospect.

The invention discloses a traditional Chinese medicine monomer composition derived from chrysanthemum plants and used for treating diabetic retinopathy as well as a preparation method and application of the traditional Chinese medicine monomer composition. The traditional Chinese medicine monomer composition prepared from the chrysanthemum plant as the raw material is high in safety, small in side effect and definite in component and is prepared according to a specific ratio, and pharmacodynamic experiments prove that compared with an ethanol extract, the traditional Chinese medicine monomer composition is more remarkable in curative effect on diabetic retinopathy, and the curative effect of the traditional Chinese medicine monomer composition on diabetic retinopathy is better than that of a traditional Chinese medicine composition on diabetic retinopathy. The composition can improve the pathological state of diabetic retinopathy from multiple targets and multiple ways, specifically can inhibit body mass increase caused by high glucose, reduce blood glucose level, improve retinal tissue structure damage, recover retinal tissue thickness, inhibit retinal cell apoptosis and inflammatory response, reduce the expression level of HIF-1alpha and VEGF protein in retinal tissue, and can be used for treating diabetic retinopathy. Scientific basis and technical support are provided for research and development of novel drugs for treating the diabetic retinopathy, and important clinical significance and market application prospects are achieved.

The present invention belongs to the field of medical technology, and specifically relates to a use of schizoflavin in the preparation of a drug for preventing or treating non-alcoholic fatty liver disease. Experiments have confirmed that the compound of the present invention can significantly improve the lipid accumulation and liver fibrosis pathological state of mice induced by a choline-deficient L-amino acid high-fat diet (CDAHFD) after oral administration, significantly reduce the levels of AST, ALT, liver hydroxyproline and TG in serum, and significantly downregulate the expression of fibrosis-related genes and inflammation-related genes in liver tissue. The compound is further expected to be developed as a drug for preventing or treating non-alcoholic liver disease. The structural formula of the compound is shown in Formula I. #imgabs0#

This invention discloses a strain of *Lactococcus gasseri* LG3092 that produces the bacteriocin GarQ and effectively antagonizes multidrug-resistant *Helicobacter pylori*, and its applications. *Lactococcus gasseri* LG3092 was deposited at the Guangdong Provincial Microbial Culture Collection Center on October 30, 2023, with accession number GDMCC No: 63939. Studies have shown that LG3092 has the following beneficial effects: (1) it can produce the bacteriocin GarQ, effectively inhibiting the growth of *Helicobacter pylori* and other common pathogenic bacteria; (2) it has a high survival rate in the stomach, can colonize the stomach, and can compete with pathogenic bacteria for binding sites, effectively reducing the infection rate of *Helicobacter pylori* in the stomach; (3) it can improve the pathological state of the stomach and alleviate inflammation. Therefore, *Lactococcus gasseri* LG3092 has great application potential in the preparation of products for the prevention or treatment of *H. pylori*, especially multidrug-resistant *H. pylori* infection.

The invention relates to a pharmaceutical composition for treating chronic atrophic gastritis and precancerous lesions and application thereof, the pharmaceutical composition is a Xiansheng stomach tonifying formula and comprises herba epimedii, codonopsis pilosula, fructus alpiniae oxyphyllae, poria cocos, roasted rhizoma atractylodis macrocephalae, caulis perllae, vinegar-processed rhizoma cyperi, galangal, rhizoma nardostachyos, vinegar-processed rhizoma sparganii, vinegar-processed curcuma zedoary, dark plum and honey-fried licorice root. The formula is scientific and reasonable, clinical research proves that the Xiansheng stomach tonifying formula has a good curative effect on clinical symptoms of patients suffering from chronic atrophic gastritis and precancerous lesions, has the effect of preventing the precancerous lesions of gastric cancer from being converted into gastric cancer, and has the effects of recovering and improving the gastric mucosa state under a gastroscope, improving the gastric mucosa quality and improving the gastric mucosa quality. The curative effect of reversing pathological changes such as atrophy, intestinal metaplasia and atypical hyperplasia and precancerous lesions is achieved; animal experiments prove that the traditional Chinese medicine composition can improve the pathological state of glandular gastric mucosa of a CAG mouse model, delay glandular gastric mucosa tissue cell senescence of the CAG mouse model and prevent gastric precancerous lesions from being converted into gastric cancer, and also has the effect of resisting gastric senescence.

The invention provides application of a multi-target melanocortin receptor stimulant in preparation of a medicine for preventing and treating pemphigus, and belongs to the technical field of medicines. The invention provides application of a compound WP302 in preparation of drugs for prevention, treatment or adjuvant treatment of pemphigus. The compound WP302 is a good MC1R, MC3R and MC4R multi-target agonist, plays a role through multiple pathophysiological mechanisms, not only has a remarkable curative effect in the aspects of oxidation resistance and inflammation resistance, but also can regulate immune response and promote tissue healing, and a brand new treatment strategy is provided. The medicine is expected to overcome the limitation of the existing treatment method, provides a safer and more effective treatment choice for pemphigus patients, and remarkably reduces long-term side effects.

This invention belongs to the field of biomedical technology, specifically relating to an isoliquiritigenin composition for improving depression and its preparation method. The isoliquiritigenin composition for improving depression comprises the following raw materials in parts by weight: 22-40 parts isoliquiritigenin, 10-17 parts N-acetyl-D-glucosamine, and 15-20 parts β-lapaquinone. Isoliquiritigenin, N-acetyl-D-glucosamine, and β-lapaquinone constitute a multi-target synergistic isoliquiritigenin composition for improving depression. Experimental results show that by taking the isoliquiritigenin composition prepared according to this invention, it can systematically exert its effects and comprehensively improve the pathological state of depression, showing broad application prospects.

The invention belongs to the technical field of biological medicines, discloses an application of a Sema3E inhibitor in preparation of a medicine for preventing, delaying or treating COPD small airway fibrosis, and proposes that the Sema3E inhibitor can be used for treating, preventing or delaying the COPD small airway fibrosis for the first time. The Sema3E inhibitor plays a role by inhibiting the expression of Sema3E. The specific molecular mechanism is as follows: by inhibiting the expression of Sema3E, inhibiting the expression of Wnt5a / b, beta-Catenin, increasing the expression of p-beta-Catenin, inhibiting the activation of a Wnt / beta-Catenin pathway, and inhibiting the activation / proliferation / migration of small airway fibroblasts. Through the mechanism, the effect of preventing, delaying or treating the COPD is achieved, and a new drug intervention target, namely Sema3E, is provided for treatment of the COPD.